MENU
+Compare
IMUX
Stock ticker: NASDAQ
AS OF
Aug 6, 11:53 AM (EDT)
Price
$0.95
Change
-$0.03 (-3.06%)
Capitalization
94.01M

IMUX Immunic Forecast, Technical & Fundamental Analysis

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis... Show more

IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for IMUX with price predictions
Aug 05, 2025

Momentum Indicator for IMUX turns positive, indicating new upward trend

IMUX saw its Momentum Indicator move above the 0 level on August 04, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

IMUX moved above its 50-day moving average on July 16, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IMUX crossed bullishly above the 50-day moving average on July 18, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMUX advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 139 cases where IMUX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for IMUX moved out of overbought territory on July 29, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for IMUX turned negative on August 01, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMUX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IMUX broke above its upper Bollinger Band on July 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMUX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.998) is normal, around the industry mean (18.071). P/E Ratio (0.000) is within average values for comparable stocks, (58.287). IMUX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.533). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (278.010).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMUX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

IMUX is expected to report earnings to fall 33.32% to -16 cents per share on August 07

Immunic IMUX Stock Earnings Reports
Q2'25
Est.
$-0.17
Q1'25
Missed
by $0.03
Q4'24
Missed
by $0.01
Q3'24
Missed
by $0.02
Q2'24
Beat
by $0.02
The last earnings report on May 08 showed earnings per share of -25 cents, missing the estimate of -22 cents. With 133.04K shares outstanding, the current market capitalization sits at 94.01M.
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals and oral therapies for the treatment of chronic inflammatory and autoimmune diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
1200 Avenue of the Americas
Phone
+1 332 255-9818
Employees
77
Web
https://www.imux.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OTLC0.05N/A
+7.84%
Oncotelic Therapeutics, Inc.
XTEPY69.76N/A
N/A
Xtep International Holdings Ltd.
CNNEF1.45N/A
N/A
Canacol Energy Ltd.
ADCNF0.65N/A
N/A
ADICON HLDGS LTD.
HAGHY54.21-0.05
-0.09%
HENSOLDT AG

IMUX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IMUX has been loosely correlated with NTLA. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if IMUX jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMUX
1D Price
Change %
IMUX100%
+0.30%
NTLA - IMUX
39%
Loosely correlated
-4.46%
PLRX - IMUX
36%
Loosely correlated
+1.76%
ERAS - IMUX
35%
Loosely correlated
+7.14%
IMNM - IMUX
35%
Loosely correlated
-0.91%
ORIC - IMUX
34%
Loosely correlated
+2.51%
More